During the past decade, University of Yamanashi Hospital conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 1 clinical trials were completed, i.e. on average, 5.6% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Yamanashi Hospital" #1 sponsor was "Bayer" with 4 trials, followed by "Celgene" with 2 trials sponsored, "Incyte Corporation" with 2 trials sponsored, "PharmaEssentia" with 2 trials sponsored and "PharmaEssentia Japan K.K." with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Yamanashi Hospital" #1 collaborator was "Niigata University Medical & Dental Hospital" with 2 trials as a collaborator, "Brightech International" with 1 trials as a collaborator, "EPS International" with 1 trials as a collaborator, "Japan Clinical Oncology Group" with 1 trials as a collaborator and "Medpace, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "University of Yamanashi Hospital" are "Primary Myelofibrosis" (4 trials), "Anemia" (3 trials), "Myelofibrosis" (3 trials), "Gastrointestinal Stromal Tumor" (2 trials) and "Metastatic Cancer" (2 trials). Many other conditions were trialed in "University of Yamanashi Hospital" in a lesser frequency.

Most popular intervention types in "University of Yamanashi Hospital" are "Drug" (17 trials), "Biological" (2 trials), "Other" (2 trials), "Procedure" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Darbepoetin alfa" (2 trials), "Molidustat (BAY85-3934)" (2 trials), "parsaclisib" (2 trials) and "placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "University of Yamanashi Hospital" are 21 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "University of Yamanashi Hospital". 1 are not yet recruiting, 8 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in University of Yamanashi Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in University of Yamanashi Hospital, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".